Examination of the Nitric Oxide Production-Suppressing Component in Tinospora tuberculata by Yokozawa Takako et al.
Tinospora tuberculata, a plant belonging to the family
Menispermaceae, is distributed from the southwestern part of
China to Southeast Asia including Vietnam, Thai, Malaysia,
Indonesia and India, and is used widely as a folk medicine.
This galenical has been used for its antipyretic, abdominal
pain-relieving, antidiarrheal, detoxifying, anthelmintic and
tonic actions.1) The pharmacological mechanisms of this
agent, however, are mostly unknown. Focusing on nitric
oxide (NO), which mediates various physiological events in-
cluding defense reactions of the body and whose increase
leads to the development of various diseases,2) we previously
studied the effect of Tinospora tuberculata in mice and found
that an aqueous extract inhibited the production of NO.3,4)
The present study was designed to investigate the inhibitory
activity of the aqueous extract of Tinospora tuberculata,
using lipopolysaccharide (LPS)-stimulated macrophages.
MATERIALS AND METHODS
Reagents Thioglycollate broth was purchased from
Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Amino-
guanidine, LPS, pepstatin A, chymostatin, aprotinin, phenyl-
methylsulfonyl fluoride, b-nicotinamide adenine dinucleotide
phosphate (reduced, NADPH), flavin adenine dinucleotide
(FAD), tetrahydrobiopterin, dithiothreitol (DTT), lactate de-
hydrogenase (LDH) and sodium pyruvate were purchased
from Sigma Chemical Co. (St. Louis, MO, U.S.A.).
Fractionation and Purification of Tinospora tuberculata
As shown in Fig. 1, dried stems of Tinospora tuberculata
(1 kg) were powdered and extracted with water (3 l) at 60—
70 °C three times. The residue was further extracted with
methanol (3 l) three times at room temperature. The aqueous
extract was concentrated and partitioned between ethyl ac-
etate and water five times to give ethyl acetate extract (frac-
tion A, 7.7 g). The acqueous layer was further separated into
three fractions [fractions B (110 g), C (29.6 g), D (7.1 g)] by
Diaion HP-20SS column chromatography with water con-
taining increasing proportions of methanol. The methanol
extract was also partitioned between ethyl acetate and water
to afford ethyl acetate extract (fraction E, 15.2 g) and an
aqueous layer (fraction F, 16.6 g). The biologically active
fraction E (14.3 g) was further separated by silica gel column
chromatography (chloroform–methanol–water) into five frac-
tions [fractions E-1 (1.39 g), E-2 (4.42 g), E-3 (2.73 g), E-4
(3.01 g), E-5 (3.25 g)]. The major constituent of fraction E-3
(1.7 g) was purified by Sephadex LH-20 (80% methanol) fol-
lowed by silica gel column chromatography (hexane–ethyl
acetate, 1 : 2) to yield N-trans-feruloyltyramine (370 mg),
which was identified by spectral comparison.
Spectral Data of N-trans-Feruloyltyramine A white
powder, FAB-MS m/z: 314 (M1H)1, IR (diffusive reflection)
nmax cm21: 3300, 1652, 1587, 1510. UV lmaxEtOH nm (e): 292
(13600), 319 (16600). 1H-NMR (300 MHz, DMSO-d6) d :
7.987 (1H, t, J55.7 Hz, NH), 7.311 (1H, d, J515.7 Hz, H-
79), 7.112 (1H, d, J51.8 Hz, H-29), 7.016 (2H, br d, J58.5
Hz, H-2, 6), 6.983 (1H, dd, J51.8, 8.1 Hz, H-69), 6.789 (1H,
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The component of aqueous Tinospora tuberculata extract that inhibits nitric oxide (NO) production was ex-
amined using macrophages activated by the addition of lipopolysaccharide. The aqueous extract was partitioned
with ethyl acetate. The aqueous layer was fractionated with a Diaion column. The residue of the aqueous extract
was extracted with methanol, and partitioned with ethyl acetate. The ethyl acetate layer was found to be associ-
ated with a distinct decrease in the NO level and inducible NO synthase. On further fractionation, the subfrac-
tion of E-3 showed high anti-NO activity. N-trans-Feruloyltyramine isolated from E-3 was identified as exhibiting
strong anti-NO activity. This compound is the most active component of Tinospora tuberculata with respect to the
suppression of NO production.
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Fig. 1
d, J58.1 Hz, H-59), 6.683 (2H, br d, J58.5 Hz, H-3, 5), 6.341
(1H, d, J515.7 Hz, H-89), 3.808 (3H, s, OCH3), 3.357 (2H,
dt, J55.7, 7.4 Hz, H-8), 2.647 (2H, t, J57.4 Hz, H-7). 13C-
NMR (75 MHz, DMSO-d6) d : 165.7 (C-99), 155.6 (C-4),
148.2, 147.8 (C-39, 49), 138.9 (C-79), 129.5 (C-1), 129.4 (C-
2, 6), 126.4 (C-19), 121.5 (C-69), 119.0, 115.6, 110.8 (C-29,
59, 89), 115.0 (C-2, 6), 55.5 (OCH3), 40.7 (C-8), 34.4 (C-7).
Animals Male BALB/c strain mice (Japan SLC, Inc.,
Hamamatsu, Japan), 6 weeks of age, were used. This study
complied with the “Guidelines for Animal Experimentation”
approved by Toyama Medical and Pharmaceutical University.
They were kept in an air-conditioned room with lighting
from 7 a.m. to 7 p.m. and given commercial pellet chow
(Clea Japan Inc., Tokyo, Japan; comprising 24.0% protein,
3.5% lipid and 60.5% carbohydrate) and water ad libitum.
Cell Culture and Assay According to the method of
Lefkowitz et al.,6) mice were injected intraperitoneally with
1.5 ml of a 4% thioglycollate broth. After 4 d, the animals
were sacrificed by cervical dislocation. Peritoneal lavage was
performed using cold RPMI 1640 medium. Peritoneal
macrophages were centrifuged at 10003g for 2 min, and the
sedimented cells were resuspended at a density of 13106/ml
in 5% fetal calf serum (FCS)-supplemented RPMI 1640
medium. The cell suspension was added to each well of a 6-
well or 96-well tissue culture plate. After 2 h of incubation in
a humidified 5% CO2 atmosphere at 37 °C, the medium was
removed and cells were washed with phosphate buffered
saline (PBS) to remove those that were nonadherent. The
Tinospora tuberculata sample or aminoguanidine with
10 mg/ml LPS was then added to each well. The plates were
incubated in a humidified 5% CO2 atmosphere at 37 °C for
24 h. Aliquots of the medium were used to measure NO and
cell viability. Nitrite was used as an indicator of NO produc-
tion and measured by a microplate assay method based on
the Griess reaction.7) Cell viability was estimated by the 3-
(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bro-
mide (MTT) assay.8) For the assay of cell lysates, cells were
washed three times with PBS, scraped into cold PBS, and
centrifuged at 5003g for 10 min at 4 °C. The cell pellet ob-
tained was resuspended in 0.5 ml of 40 mM Tris–buffer (pH
8.0) containing 5 mg/ml pepstatin A, 1 mg/ml chymostatin,
5 mg/ml aprotinin and 100 mM phenylmethylsulfonyl fluoride,
and lysed by three cycles of freeze-thawing. Aliquots of the
lysate were used for the determination of inducible NO syn-
thase (iNOS) activity, and protein assay. iNOS activity was
measured as described previously.9) Briefly, 10—20 mg of
cell lysate protein was incubated in 20 mM Tris–HCl (pH
7.9), containing 4 mM FAD, 4 mM tetrahydrobiopterin, 3 mM
DTT, and 2 mM each of L-arginine (L-Arg) and NADPH. The
reaction was carried out in duplicate for 180 min at 37 °C in
96-well plates. Residual NADPH was oxidized enzymatically
with 10 units/ml LDH and 5 mM sodium pyruvate in a final
volume of 130 m l, with incubation for a further 5 min at
37 °C, and the Griess assay was performed as above.7) Pro-
tein was determined by the micro-biuret method,10) with
bovine serum albumin as a standard.
Statistics Results were assessed by analysis of variance,
followed by Dunnett’s test. Significance was accepted at
p,0.05.
RESULTS
NO Production Exposure to LPS induced the produc-
tion of a large amount of NO, about 6.9-fold that observed in
the blank. When macrophages were cultured under identical
conditions, but with different doses of Tinospora tuberculata
extract, NO production was substantially inhibited in a con-
centration-dependent manner, as shown in Table 1. After sep-
aration of the extract, a significant difference in inhibitory
activity was observed among the various fractions. The in-
hibitory activity of fractions C and F was weaker than that of
the extract as a whole. In contrast, fraction E showed an ap-
parent activity that was stronger than the extract. We further
separated fraction E. Of the subfractions obtained, E-3 had
the highest activity, inducing the production of 9.08 mM of
NO at 50 mg/ml and 6.39 mM at 100 mg/ml. Fractions E-1 and
E-5, by contrast, had no ameliorative effect on production.
We next examined N-trans-feruloyltyramine isolated from
fraction E-3 and found that it inhibited NO production in a
concentration-dependent manner, as shown in Table 1. The
inhibition induced by 50 mg/ml N-trans-feruloyltyramine re-
sembled that induced by 100 mM aminoguanidine.
iNOS Activity In activated macrophages, enhanced for-
mation of NO was associated with the expression of iNOS
activity. As shown in Table 1, exposure of macrophages to
LPS caused a significant increase in iNOS activity from 6.89
to 27.66 pmol/mg protein/min. Treatment of the cells with
Tinospora tuberculata extract inhibited iNOS activity in a
concentration-dependent manner. iNOS activity was de-
creased approximately to 86, 72 and 66% of LPS-stimulated
control values, in 50, 100 and 200 mg/ml of Tinospora tuber-
culata extract-treated cells, respectively. Examination of its
fractions showed that fraction E possessed higher inhibitory
activity than the extract itself. Among the subfractions ob-
tained from fraction E, fraction E-3 appeared to most
strongly inhibit iNOS activity, while such activity was passed
into N-trans-feruloyltyramine isolated from fraction E-3. The
inhibition induced by 50 mg/ml N-trans-feruloyltyramine re-
sembled that induced by 100 mM aminoguanidine.
Cell Viability To test and verify that the inhibitory effect
of the Tinospora tuberculata extract, fraction and component
on NO production was not due to cytotoxicity, we examined
their effect on the viability of activated macrophages. As
shown in Table 1, LPS impaired cell viability significantly as
compared with nontreated cells. However, it was found that
the cytotoxic effect of LPS was attenuated by incubation with
Tinospora tuberculata extract and its fractions except B, C
and E-1. N-trans-Feruloyltyramine was also able to protect
cells that had been exposed to LPS. Although N-trans-feru-
loyltyramine improved the cell viability, aminoguanidine ap-
peared to have no ameliorative effect on the cytotoxicity due
to LPS.
DISCUSSION
Living organisms utilize the chemical properties of NO for
the intracellular and intercellular processes of cGMP-medi-
ated communication. NO itself is cytotoxic, however, and
produces secondary active substances through a reaction
with oxygen and active oxygen species. Therefore, the pro-
duction of a substantial amount of NO due to increased im-
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munological activity can cause disease. Thus, the NO pro-
duced at the site of infection by inflammatory cells such 
as macrophages and neutrophils, or by epithelial cells
(bronchus, bowel), is attracting attention as a mediator of in-
flammatory responses. Macrophages are known to produce
NO through the metabolism of L-Arg by NOS promptly in re-
sponse to stimulation at the site of infection, inflammation,
and immune responses.2) However, excessive production of
NO may cause shock and injury to living tissue. In light of
this, an effort is now being made to develop a specific NOS
inhibitor effective in macrophages.11—13)
We have previously reported that the aqueous extract 
of Tinospora tuberculata inhibited NO production in
macrophages in a dose-dependent manner.3) The effects of
Tinospora tuberculata were also evident in a cell-free sys-
tem; Tinospora tuberculata inhibited the production of NO
from L-Arg and hydrogen peroxide, and dose-dependently
suppressed the release of NO donors from sodium nitroprus-
side.4) In the present study, we investigated the active compo-
nent of Tinospora tuberculata, using macrophages.
Macrophages stimulated by LPS produced a large quantity
of NO, with increased iNOS activity and decreased cell via-
bility. In macrophages treated with a stepwise dose of
Tinospora tuberculata extract, the level of NO and the iNOS
activity were suppressed in a dose-dependent manner, while
cell viability was increased. Tinospora tuberculata was then
examined to establish the component responsible for the ac-
tivity found in its aqueous extract. Six fractions were ob-
tained from aqueous Tinospora tuberculata extract and its
residue. The residue was then extracted with methanol, and
the methanol extract was partitioned with ethyl acetate. The
ethyl acetate layer thus obtained was found to have the most
activity. Fractions having a bitter taste characteristic of this
galenical had no effect, suggesting that borapetosides A, B, C
and D, and borapetol B have no activity to inhibit the produc-
tion of NO. The ethyl acetate layer, containing a large quan-
October 2001 1155
Table 1. NO Production, iNOS Activity and Cell Viability of Macrophages Incubated with LPS
Group
NO iNOS Cell viability
(mM) (pmol/mg protein/min) (%)
None 5.7960.32 6.8960.68 100.061.1
LPS-treatment
Control 39.9360.36c 27.6660.88c 79.661.8c
Extract (50 mg/ml) 36.2660.77c,f 23.7861.01c,f 81.660.9c
Extract (100 mg/ml) 22.5960.49c,f 19.9260.71c,f 82.461.7c,d
Extract (200 mg/ml) 14.6760.58c,f 18.1360.54c,f 83.960.9c,f
Fraction A (50 mg/ml) 32.6960.70c,f 23.0160.95c,f 80.862.7c
Fraction A (100 mg/ml) 28.8460.43c,f 21.9060.55c,f 81.760.4c
Fraction A (200 mg/ml) 17.0960.74c,f 19.9861.12c,f 82.860.4c,d
Fraction B (50 mg/ml) 57.7962.28c,f 39.5062.90c,f 79.661.4c
Fraction B (100 mg/ml) 33.4661.62c,d 22.1261.09c,f 79.763.4c
Fraction B (200 mg/ml) 22.8461.20c,f 19.0060.79c,f 80.760.9c
Fraction C (50 mg/ml) 54.1764.67c,f 37.6962.71c,f 78.660.4c
Fraction C (100 mg/ml) 52.4063.41c,f 36.0161.98c,f 76.362.7c
Fraction C (200 mg/ml) 42.9964.63c 28.7161.47c 78.262.4c
Fraction D (50 mg/ml) 66.4561.67c,f 47.0963.25c,f 79.160.9c
Fraction D (100 mg/ml) 34.9562.73c,f 25.5061.14c 82.963.8c
Fraction D (200 mg/ml) 16.6260.81c,f 19.0060.86c,f 86.461.3c,e
Fraction E (50 mg/ml) 23.8660.83c,f 20.1660.59c,f 95.460.7f
Fraction E (100 mg/ml) 15.0360.70c,f 18.7160.78c,f 113.863.6c,f
Fraction E (200 mg/ml) 8.5760.21a,f 16.2960.87c,f 121.963.7c,f
Fraction F (50 mg/ml) 73.2064.76c,f 53.0863.06c,f 78.561.7c
Fraction F (100 mg/ml) 49.0062.27c,f 33.1562.11c,f 82.662.6c
Fraction F (200 mg/ml) 33.8162.90c,e 20.7762.59c,f 91.161.2c,f
LPS-treatment
Control 44.6360.71c 29.9160.82c 79.361.7c
Fraction E-1 (50 mg/ml) 44.7261.43c 30.9060.49c 77.661.1c
Fraction E-1 (100 mg/ml) 34.9160.97c,f 26.7160.39c,f 79.561.2c
Fraction E-2 (50 mg/ml) 23.6860.43c,f 24.9760.54c,f 79.560.7c
Fraction E-2 (100 mg/ml) 9.6660.53c,f 18.7361.00c,f 82.861.4c,d
Fraction E-3 (50 mg/ml) 9.0860.85c,f 17.9860.71c,f 85.362.0c,f
Fraction E-3 (100 mg/ml) 6.3960.22f 12.5360.55c,f 112.163.2c,f
Fraction E-4 (50 mg/ml) 28.9460.56c,f 26.0160.77c,f 103.961.7a,f
Fraction E-4 (100 mg/ml) 13.1261.43c,f 18.4961.02c,f 132.662.0c,f
Fraction E-5 (50 mg/ml) 39.3360.83c,f 28.0961.23c,d 88.361.2c,f
Fraction E-5 (100 mg/ml) 26.6060.75c,f 26.1160.48c,f 95.561.3b,f
LPS-treatment
Control 43.4660.62c 29.6560.58c 78.061.2c
N-trans-Feruloyltyramine (10 mg/ml) 9.2260.46c,f 17.6660.72c,f 89.062.7c,f
N-trans-Feruloyltyramine (20 mg/ml) 8.4860.12c,f 16.0661.01c,f 91.161.9c,f
N-trans-Feruloyltyramine (50 mg/ml) 6.8760.16c,f 12.8861.13c,f 99.361.7f
N-trans-Feruloyltyramine (100 mg/ml) 3.8760.19c,f 6.0560.59f 112.262.7c,f
Aminoguanidine (100 mM) 7.0760.20c,f 11.0860.49c,f 81.061.3c
Significance: a p,0.05, b p,0.01, c p,0.001 vs. non-treatment values, d p,0.05, e p,0.01, f p,0.001 vs. LPS-treatment control values.
tity of N-trans-feruloyltyramine, was divided into 5 fractions
with a silica gel column. The fraction richest in N-trans-feru-
loyltyramine proved to have the highest level of activity to
inhibit the NO production. It became apparent that the com-
ponent responsible for the inhibitory activity of Tinospora tu-
berculata was N-trans-feruloyltyramine isolated from this
fraction. The present study revealed a new effect of this com-
ponent, the suppression of NO production from macrophages,
in parallel with the suppression of iNOS activity. This anti-
NO activity was comparable to the effect of aminoguanidine,
a specific inhibitor of iNOS.
N-trans-Feruloyltyramine was found in the stem of dried
Tinospora tuberculata by Fukuda et al.,5) and has been de-
tected in eggplants14) and leeks.15) However, little is known
about the physiological activity of N-trans-feruloyltyramine,
though a marked inhibitory effect of this compound on
platelet aggregation was reported by Okuyama et al.15) The
inhibition of NO production via iNOS is a new effect of
Tinospora tuberculata demonstrated in the present study.
However, it is presumed that the NO produced by macro-
phages through metabolism of L-Arg protects the body in 
cooperation with the cytokine network centering on inter-
feron-g and other defense factors (active oxygen, etc.), rather
than independently by itself.16,17) On the other hand, Tracey et
al.18) demonstrated that purified NOS from brain (neuron
NOS), macrophages (iNOS) and endothelium (endothelial
NOS) all showed NADPH-diaphorase activity; the relative
activities were: macrophage.endothelium.brain. These
data indicate that all known NOSs are NADPH-diaphorases.
Mitchell et al.19) have also published data showing that in
macrophages, both NADPH-diaphorase and NOS activities
can be induced by LPS. Moreover, NADPH-diaphorase ac-
tivity appeared in the peritoneal macrophages of LPS-pre-
treated mice after the induction of pancreatitis, and the ele-
vated NO was inhibited by NG-nitro-L-arginine.20) Although
further studies are needed to elucidate the mechanisms by
which N-trans-feruloyltyramine exerts its inhibitory actions,
Tinospora tuberculata extract inhibited NADPH-diaphorase
activity dose-dependently.3) N-trans-Feruloyltyramine seems
to suppress NO production due to inhibition of NADPH-di-
aphorase.
The ideal NO inhibitor would block only the harmful ef-
fects of NO, while maintaining or enhancing the beneficial
effects. Recent studies have yielded several compounds
which have very high activity and relatively high selectivity.
Aminoguanidine is among these compounds and attracting
attention as a specific iNOS inhibitor.21) N-trans-Feruloyl-
tyramine at 50 mg/ml was found to have a level of activity
equivalent to 100 mM of aminoguanidine. However, unlike
aminoguanidine, the cell viability decreased by LPS was re-
stored in the presence of this compound, demonstrating the
very low toxicity of this iNOS inhibitor.
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